Patients with MASH experience worse health-related quality of life: a multinational real-world study using LiverMultiScan

26 October 2026

This study presents the HRQoL from a large, randomised controlled trial that took place in several European countries. Across all jurisdictions, self-care and usual activities had the lowest HRQoL scoring, whilst pain/discomfort had the highest. There were no differences between reported HRQoL in the study arms, however within the imaging arm, those with metabolic dysfunction-associated steatohepatitis (MASH) and therefore higher corrected T1 values, reported a lower HRQoL compared to those with metabolic dysfunction-associated steatotic liver disease (MASLD). These findings provide important evidence linking non-invasive tests to patient reported outcomes that may be incorporated into economic evaluations and clinical risk stratification pathways in the MASLD/MASH space.